| Literature DB >> 35954024 |
Ewelina Maślak1,2, Michał Złoch1,2, Adrian Arendowski2, Mateusz Sugajski2, Izabela Janczura3, Joanna Rudnicka1, Justyna Walczak-Skierska1, Magdalena Buszewska-Forajta4, Katarzyna Rafińska1, Paweł Pomastowski2, Dorota Białczak3, Bogusław Buszewski1,2.
Abstract
The presence of certain microorganisms in dairy products or silage is highly desirable. Among them are probiotic strains of lactic acid bacteria (LAB), which show many beneficial features, including antimicrobial properties that support the development of beneficial microflora; in addition, owing to their biochemical activity, they influence the nutritional, dietary, and organoleptic properties of food products. Before being placed on the market, each strain requires separate testing to determine its probiotic properties and effectiveness. The aim of this study was to isolate LAB strains from a pickled beetroot sample that could be used in the dairy industry and with the potential to be considered as a probiotic in the future. Two strains identified using the MALDI technique were selected-Lactococcus lactis and Weissella cibaria. The optimal growth conditions of the strains were determined, and their proteolytic properties were assessed with the use of the o-PA reagent and spectrophotometry. The lipid profile was analyzed using the SALDI (surface-assisted laser desorption/ionization) technique and silver nanoparticles. High-performance liquid chromatography was used to assess the ability of the strains to synthesize beneficial metabolites, such as B vitamins (B2, B3, and B9) or lactic acid, and gas chromatography was used to analyze the substances responsible for organoleptic properties. Moreover, the ability to inhibit the growth of pathogenic strains was also tested in the selected strains. Both tested strains demonstrated the desired properties of starter cultures for future use in functional food production, showing that fermented plant products can serve as valuable potential probiotic sources.Entities:
Keywords: B vitamins; lactic acid bacteria; laser desorption/ionization; metabolites
Year: 2022 PMID: 35954024 PMCID: PMC9368051 DOI: 10.3390/foods11152257
Source DB: PubMed Journal: Foods ISSN: 2304-8158
Conditions for the detection of the analyzed compounds. B2—riboflavin; B3—niacin; B9—folic acid; L—lactose; LA—lactic acid.
| Retention Time (Min) | Ionization | Molecular Ion | Fragment Ion | Q1 (V) | CE | Q3 (V) | |
|---|---|---|---|---|---|---|---|
|
| 3.811 | Positive | 337 | 243 | −20 | −25 | −20 |
|
| 1.247 | Positive | 124 | 79 | −10 | −24 | −15 |
|
| 2.971 | Positive | 442 | 176 | −16 | −39 | −19 |
|
| 1.060 | Negative | 341 | 161.15 | 13 | 8 | 15 |
|
| 1.594 | Negative | 89.25 | 43.05 | 19 | 13 | 14 |
Validation of the analytical method. LOD—limit of detection; LOQ—limit of quantification.
| Linearity (µg/mL) | R2 | Standard Curve Equation | LOD (µg/mL) | LOQ (µg/mL) | |
|---|---|---|---|---|---|
|
| 0.005–10 | 0.9941 | y = 1,137,260x − 89,427 | 0.001 | 0.0033 |
|
| 0.25–10 | 0.9985 | y = 8819.9x − 1000.03 | 0.050 | 0.1650 |
|
| 0.025–10 | 0.9980 | y = 104,830x + 11,539 | 0.005 | 0.0165 |
|
| 0.01–400 | 0.9963 | y = 19,947x + 122,904 | 0.005 | 0.0165 |
|
| 0.01–2000 | 0.9972 | y = 18,770x + 651,622 | 0.005 | 0.0165 |
Comparison of identification results between the MALDI and 16S rRNA techniques.
| Identification by MALDI | 16S rRNA Identification | Number in PCM ** | |||
|---|---|---|---|---|---|
| Identification Result | MSP Log Score * | Identification Result | % Similarity | Strand Length (bp) | |
| 2.02 | 99.86 | 1412 | |||
| 2.13 | 99.58 | 1442 | |||
* log score >2.00—secure genus identification, probable species identification. ** PCM—Polish Collection of Microorganisms.
Figure 1Optical microscope photos of the Gram staining of the tested strains: (A)—Lactococcus lactis; (B)—Weissella cibaria.
Figure 2Graphs showing the growth of the tested LAB strains in various culture media and temperatures.
Figure 3Calibration curve showing the dependence of absorbance on the concentration of glycine.
Figure 4GC/MS chromatograms of control sample (MRS agar) and analyzed LAB strain samples.
SALDI mass spectrum of Lactococcus lactis lipid extract made on an AgNLET plate with electroplated silver nanoparticles (S/N ≥ 5, Δ max. ± 10 ppm).
|
| |||||
|---|---|---|---|---|---|
| Compound * | Adduct Formula | Δ (ppm) | |||
|
| [FA oxo(15:0)] 4-oxo-pentadecanoic acid | [C15H28O3 + 107Ag]+ | 363.108 | 363.108 | 0.0 |
|
| [FA hydroxy(17:2)]12-hydroxy-8E,10Eheptadecadienoic acid | [C17H30O3 + 107Ag]+ | 389.123 | 389.124 | −2.6 |
|
| Dehydroabietadienal | [C20H28O + 107Ag]+ | 391.120 | 391.119 | 2.6 |
| [C20H28O + 109Ag]+ | 393.119 | 393.118 | 2.5 | ||
|
| [GP (6:0/6:0)] 1,2-dihexanoyl-sn-glycero-3-phosphate | [C15H29O8P + K]+ | 407.123 | 407.123 | 0.0 |
|
| Ala-Leu-Ala-Gly | [C14H26N4O5 + 107Ag]+ | 437.096 | 437.095 | 2.3 |
|
| Met-Phe-Cys | [C17H25N3O4S2 + K]+ | 438.093 | 438.092 | 2.3 |
|
| Cys-Trp-Gly-Gly | [C18H23N5O5S + Na]+ | 444.130 | 444.131 | −2.3 |
|
| Asn-Thr-Cys-Ser | [C14H25N5O8S + Na]+ | 446.132 | 446.132 | 0.0 |
|
| Ala-Ala-Ala-Asp | [C13H22N4O7 + 107Ag]+ | 453.052 | 453.053 | −2.2 |
|
| Ala-Asn-Gly-Ser | [C12H21N5O7 + 107Ag]+ | 454.050 | 454.049 | 2.2 |
|
| [GP (6:0/6:0)] 1,2-dihexanoyl-sn-glycero-3-phosphate | [C15H29O8P + 107Ag]+ | 475.066 | 475.065 | 2.1 |
|
| Val-Asp-His | [C15H23N5O6 + 107Ag]+ | 476.069 | 476.069 | 0.0 |
|
| [GP (6:0/6:0)] 1,2-dihexanoyl-sn-glycero-3-phosphate | [C15H29O8P + 109Ag]+ | 477.065 | 477.064 | 2.1 |
|
| PA(17:2(9Z,12Z)/0:0) | [C20H37O7P + 109Ag]+ | 529.130 | 529.132 | −3.8 |
|
| Ala-Trp-Val-Tyr | [C28H35N5O6 + H]+ | 538.267 | 538.266 | 1.9 |
|
| C12-ACP (Dodecanoyl-ACP) | [C23H44N2O8PS + H]+ | 540.263 | 540.263 | 0.0 |
|
| LysoPE(20:3(8Z,11Z,14Z)/0:0) | [C25H46NO7P + K]+ | 542.259 | 542.264 | −9.2 |
|
| Asp-Leu-Met-His | [C21H34N6O7S + K]+ | 553.184 | 553.184 | 0.0 |
|
| Alpha-Trisaccharide | [C20H37NO14 + K]+ | 554.187 | 554.185 | 3.6 |
|
| Ala-Ala-Tyr-His | [C21H28N6O6 + 109Ag]+ | 569.110 | 569.111 | −1.8 |
|
| Glu-Phe-Ala-Pro | [C22H30N4O7 + 109Ag]+ | 571.116 | 571.116 | 0.0 |
|
| Cys-Pro-Pro-Tyr | [C22H30N4O6S + 107Ag]+ | 585.094 | 585.093 | 1.7 |
|
| Ala-Cys-Tyr-His | [C21H28N6O6S + 107Ag]+ | 599.084 | 599.084 | 0.0 |
| [C21H28N6O6S + 109Ag]+ | 601.085 | 601.083 | 3.3 | ||
|
| Cellotriose | [C18H32O16 + 109Ag]+ | 613.075 | 613.073 | 3.3 |
|
| Octacosanyl hexadecanoate | [C44H88O2 + H]+ | 649.684 | 649.686 | −3.1 |
|
| FAD stem group | [C15H26N6O13P2 + 109Ag]+ | 669.009 | 669.008 | 1.5 |
|
| GalCer(d18:2/20:0) | [C44H83NO8 + H]+ | 754.621 | 754.619 | 2.7 |
|
| TG(13:0/13:0/17:2(9Z,12Z)) | [C46H84O6 + Na]+ | 755.614 | 755.616 | −2.6 |
|
| PC(18:2(9Z,12Z)/P-18:1(11Z)) | [C44H82NO7P + H]+ | 768.592 | 768.590 | 2.6 |
|
| [PC (16:2/18:1)] 1-hexadecyl-2-(9Z-octadecenyl)sn- glycero-3-phosphocholine | [C42H86NO6P + K]+ | 770.587 | 770.582 | 6.5 |
|
| PA(19:0/22:2(13Z,16Z)) | [C44H83O8P + H]+ | 771.584 | 771.590 | −7.8 |
|
| PC(15:0/20:2(11Z,14Z)) | [C43H82NO8P + H]+ | 772.582 | 772.585 | −3.9 |
|
| PG(P-20:0/17:2(9Z,12Z)) | [C43H81O9P + H]+ | 773.572 | 773.569 | 3.9 |
|
| PC(14:1(9Z)/18:3(6Z,9Z,12Z)) | [C40H72NO8P + 109Ag]+ | 834.407 | 834.404 | 3.6 |
|
| [PE (6:0/8:0)] 1-(6-[ | [C43H72NO6P + 107Ag]+ | 836.407 | 836.414 | −8.4 |
|
| [PC (18:1/22:6)] 1-(11Z-octadecenoyl)-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphocholine | [C48H82NO8P + K]+ | 870.543 | 870.541 | 2.3 |
|
| PI(16:1(9Z)/19:1(9Z)) | [C44H81O13P + Na]+ | 871.535 | 871.531 | 4.6 |
|
| PS(O-20:0/16:0) | [C42H84NO9P + 109Ag]+ | 886.494 | 886.493 | 1.1 |
|
| PI(15:0/20:2(11Z,14Z)) | [C44H81O13P + K]+ | 887.497 | 887.505 | −9.0 |
|
| PE(P-18:0/22:4(7Z,10Z,13Z,16Z)) | [C45H82NO7P + 109Ag]+ | 888.495 | 888.487 | 9.0 |
|
| PS(O-16:0/21:0) | [C43H86NO9P + 107Ag]+ | 898.505 | 898.509 | −4.5 |
|
| PI(16:0/20:3(8Z,11Z,14Z)) | [C45H81O13P + K]+ | 899.504 | 899.505 | −1.1 |
|
| (3′-sulfo)Galbeta-Cer(d18:1/2-OH-16:0) | [C40H77NO12S + 107Ag]+ | 902.422 | 902.421 | 1.1 |
|
| PG(16:1(9Z)/22:4(7Z,10Z,13Z,16Z)) | [C44H77O10P + 107Ag]+ | 903.428 | 903.430 | −2.2 |
|
| PE(22:1(13Z)/24:1(15Z)) | [C51H98NO8P + Na]+ | 906.688 | 906.692 | −4.4 |
|
| PS(15:0/22:1(11Z)) | [C43H82NO10P + 107Ag]+ | 910.468 | 910.472 | −4.4 |
|
| PC(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)) | [C46H78NO8P + 109Ag]+ | 912.451 | 912.451 | 0.0 |
|
| PG(P-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | [C46H79O9P + 107Ag]+ | 913.450 | 913.451 | −1.1 |
|
| (3′-sulfo)GalBeta-Cer(d18:1/18:0) | [C42H81NO11S + 107Ag]+ | 914.455 | 914.458 | −3.3 |
|
| PI(P-16:0/17:0) | [C42H81O12P + 107Ag]+ | 915.455 | 915.451 | 4.4 |
|
| (3′-sulfo)GalBeta-Cer(d18:1/18:0) | [C42H81NO11S + 109Ag]+ | 916.463 | 916.457 | 6.5 |
|
| PI(O-16:0/18:3(9Z,12Z,15Z)) | [C43H79O12P + 109Ag]+ | 927.437 | 927.435 | 2.2 |
|
| PS(17:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z)) | [C45H76NO10P + 107Ag]+ | 928.421 | 928.425 | −4.3 |
|
| PS(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | [C46H76NO10P + 107Ag]+ | 940.430 | 940.425 | 5.3 |
|
| PI(16:1(9Z)/18:1(9Z)) | [C43H79O13P + 107Ag]+ | 941.432 | 941.430 | 2.1 |
|
| [PE (22:6/22:6)] 1,2-di-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoethanolamine | [C49H74NO8P + 107Ag]+ | 942.413 | 942.420 | −7.4 |
|
| GalCer(d18:0/26:1) | [C50H97NO8 + 109Ag]+ | 948.626 | 948.626 | 0.0 |
|
| [GL (18:0/20:0/20:0)] 1-octadecanoyl-2,3-dieicosanoyl-sn-glycerol | [C61H118O6 + K]+ | 985.857 | 985.856 | 1.01 |
|
| [PC (24:0/26:0)] 1-tetracosanoyl-2-hexacosanoyl-sn- glycero-3-phosphocholine | [C58H116NO8P + H]+ | 986.859 | 986.851 | 8.1 |
|
| PE(22:2(13Z,16Z)/24:1(15Z)) | [C51H96NO8P + 109Ag]+ | 990.593 | 990.592 | 1.0 |
|
| [GP (18:0/18:0/2:0/2:0)] 1,2-di-(9Z-octadecenoyl)-sn- glycero-3-cytidine-5′-diphosphate | [C48H85N3O15P2 + H]+ | 1006.555 | 1006.552 | 3.0 |
|
| Siroheme amide | [C42H47FeN5O15 + 107Ag]+ | 1024.151 | 1024.146 | 4.9 |
|
| 2-Oxo-delta3-4,5,5-trimethylcyclopentenylacetyl-CoA | [C31H48N7O18P3S + 109Ag]+ | 1040.106 | 1040.103 | 2.9 |
|
| CoA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | [C43H66N7O17P3S + 107Ag]+ | 1184.255 | 1184.249 | 5.1 |
| [C43H66N7O17P3S + 109Ag]+ | 1186.246 | 1186.249 | −2.5 | ||
* Putative metabolite.
SALDI mass spectrum of Weissella cibaria lipid extract made on an AgNLET plate with electroplated silver nanoparticles (S/N ≥ 5, Δ max. ± 10 ppm).
|
| |||||
|---|---|---|---|---|---|
| Compound * | Adduct Formula | Δ (ppm) | |||
|
| [FA hydroxy(15:0)] 2-hydroxy-pentadecanoic acid | [C15H30O3 + 107Ag]+ | 365.12 | 365.12 | 0.0 |
|
| N-palmitoyl proline | [C21H39NO3 + Na]+ | 376.28 | 376.28 | 0.0 |
|
| Galactan | [C14H26O11 + Na]+ | 393.14 | 393.14 | 0.0 |
|
| [PC (6:0)] 1-hexanoyl-sn-glycero3-phosphocholine | [C14H30NO7P + K]+ | 394.14 | 394.14 | 0.0 |
|
| 2-hydroxy-9Z,12Z,15Z-octadecatrienoic acid | [C18H30O3 + 109Ag]+ | 403.12 | 403.12 | 0.0 |
|
| Met-Tyr | [C14H20N2O4S + 107Ag]+ | 419.02 | 419.02 | 0.0 |
|
| [PC (3:0)] 1-(2E-propionyl)sn-glycero-3- phosphocholine | [C11H22NO7P + 109Ag]+ | 420.02 | 420.02 | 0.0 |
|
| S-(2-Chloroacetyl)glutathione | [C12H18N3O7ClS + K]+ | 422.02 | 422.02 | 0.0 |
|
| Val-Gly-Arg | [C13H26N6O4 + 107Ag]+ | 437.11 | 437.11 | 0.0 |
|
| S-Adenosylmethionine | [C15H23N6O5S + K]+ | 438.11 | 438.11 | 0.0 |
|
| Ala-Cys-Gly-Arg | [C14H27N7O5S + K]+ | 444.14 | 444.14 | 0.0 |
|
| Phe-Trp-Gly | [C22H24N4O4 + K]+ | 447.14 | 447.14 | 0.0 |
|
| Asp-Gly-Arg | [C12H22N6O6 + 107Ag]+ | 453.07 | 453.06 | 22.1 |
|
| Ala-Ala-Ala-Asn | [C13H23N5O6 + 109Ag]+ | 454.07 | 454.07 | 0.0 |
|
| Dopaxanthin | [C18H18N2O8 + 107Ag]+ | 497.01 | 497.01 | 0.0 |
| [C18H18N2O8 + 109Ag]+ | 499.01 | 499.01 | 0.0 | ||
|
| CPA(18:2(9Z,12Z)/0:0) | [C21H37O6P + 109Ag]+ | 525.14 | 525.14 | 0.0 |
|
| CPA(18:1(11Z)/0:0) | [C21H39O6P + 109Ag]+ | 527.15 | 527.15 | 0.0 |
|
| Ile-Lys-Tyr | [C21H34N4O5 + 107Ag]+ | 529.16 | 529.16 | 0.0 |
|
| PS(17:2(9Z,12Z)/0:0) | [C23H42NO9P + Na]+ | 530.25 | 530.25 | 0.0 |
|
| PA(17:0/0:0) | [C20H41O7P + 107Ag]+ | 531.16 | 531.16 | 0.0 |
|
| Arg-Ile-Ile-Pro | [C23H43N7O5 + K]+ | 536.29 | 536.30 | −18.6 |
|
| PG(12:0/0:0) | [C18H37O9P + 109Ag]+ | 537.12 | 537.12 | 0.0 |
|
| LysoPC(18:4(6Z,9Z,12Z,15Z)) | [C26H46NO7P + Na]+ | 538.29 | 538.29 | 0.0 |
|
| Ala-Glu-Ile-Thr | [C18H32N4O8 + 107Ag]+ | 539.13 | 539.13 | 0.0 |
|
| Asn-Leu-Phe-Phe | [C28H37N5O6 + H]+ | 540.28 | 540.28 | 0.0 |
|
| Ala-Phe-Val-Pro | [C22H32N4O5 + 109Ag]+ | 541.14 | 541.14 | 0.0 |
|
| His-Lys-Val-His | [C23H37N9O5 + Na]+ | 542.28 | 542.28 | 0.0 |
|
| Glu-Glu-Met-Pro | [C20H32N4O9S + K]+ | 543.15 | 543.15 | 0.0 |
|
| PC(O-10:1(9E)/2:0) | [C20H40NO7P + 107Ag]+ | 544.16 | 544.16 | 0.0 |
|
| LysoPA(0:0/18:1(9Z)) | [C21H41O7P + 109Ag]+ | 545.16 | 545.16 | 0.0 |
|
| Asn-Trp-Asp-Pro | [C24H30N6O8 + Na]+ | 553.20 | 553.20 | 0.0 |
|
| Lys-Trp-Gly-Gly | [C21H30N6O5 + 109Ag]+ | 555.13 | 555.13 | 0.0 |
|
| Ala-Cys-Tyr-Tyr | [C24H30N4O7S + K]+ | 557.14 | 557.15 | −17.9 |
|
| Arg-Asn-Asp-Gly | [C16H28N8O8 + 107Ag]+ | 567.11 | 567.11 | 0.0 |
|
| Phe-Thr-Pro-Pro | [C23H32N4O6 + 109Ag]+ | 569.14 | 569.14 | 0.0 |
|
| Thr-Trp-Arg | [C21H31N7O5 + 109Ag]+ | 570.14 | 570.14 | 0.0 |
|
| Ile-Met-Thr-Thr | [C19H36N4O7S + 107Ag]+ | 571.13 | 571.14 | −17.5 |
|
| Cys-Ser-Tyr-Tyr | [C24H30N4O8S + K]+ | 573.14 | 573.14 | 0.0 |
|
| Phe-Gly-Ser-Tyr | [C23H28N4O7 + 109Ag]+ | 581.10 | 581.10 | 0.0 |
|
| Asn-Leu-Asn-Asp | [C18H30N6O9 + 109Ag]+ | 583.11 | 583.11 | 0.0 |
|
| Ala-Phe-Asn-Gln | [C21H30N6O7 + 107Ag]+ | 585.12 | 585.12 | 0.0 |
| [C21H30N6O7 + 109Ag]+ | 587.12 | 587.12 | 0.0 | ||
|
| His-Met-Phe-Gly | [C22H30N6O5S + 107Ag]+ | 597.10 | 597.10 | 0.0 |
|
| Arg-Cys-Gln-Ser | [C17H32N8O7S + 107Ag]+ | 599.12 | 599.12 | 0.0 |
| [C17H32N8O7S + 109Ag]+ | 601.12 | 601.12 | 0.0 | ||
|
| Cys-Met-Phe-Thr | [C21H32N4O6S2 + 109Ag]+ | 609.08 | 609.08 | 0.0 |
|
| Asp-Met-Thr-His | [C19H30N6O8S + 109Ag]+ | 611.09 | 611.09 | 0.0 |
|
| Ala-Trp-Cys-Gln | [C22H30N6O6S + 107Ag]+ | 613.10 | 613.10 | 0.0 |
| [C22H30N6O6S + 109Ag]+ | 615.10 | 615.10 | 0.0 | ||
|
| Asp-Met-Asp-His | [C19H28N6O9S + 107Ag]+ | 623.07 | 623.07 | 0.0 |
|
| Cys-Met-Thr-Tyr | [C21H32N4O7S2 + 109Ag]+ | 625.08 | 625.08 | 0.0 |
|
| Poly-g-D-glutamate | [C20H30N4O12 + 109Ag]+ | 627.09 | 627.09 | 0.0 |
|
| Asn-Met-Met-Gln | [C19H34N6O7S2 + 107Ag]+ | 629.10 | 629.10 | 0.0 |
|
| P-(bromoacetamido)phenyl uridylpyrophosphate | [C17H20BrN3O13P2 + Na]+ | 637.96 | 637.95 | 15.7 |
|
| Asn-Trp-Asp-Cys | [C22H28N6O8S + 107Ag]+ | 643.08 | 643.07 | 15.6 |
|
| TG(12:0/12:0/20:0) | [C47H90O6 + H]+ | 751.68 | 751.68 | 0.0 |
|
| Stigmast-5,22E-dien-3beta-yl (13Z-docosenoate) | [C51H88O2 + Na]+ | 755.67 | 755.67 | 0.0 |
| [C51H88O2 + K]+ | 771.64 | 771.64 | 0.0 | ||
|
| PE(15:0/22:0) | [C42H84NO8P + H]+ | 762.60 | 762.60 | 0.0 |
|
| GlcCer(d18:2/21:0) | [C45H85NO8 + H]+ | 768.64 | 768.63 | 13.0 |
|
| PS(17:1(9Z)/20:4(5Z,8Z,11Z,14Z)) | [C43H74NO10P + K]+ | 834.47 | 834.47 | 0.0 |
|
| PG(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)) | [C44H77O10P + K]+ | 835.48 | 835.49 | −12.0 |
|
| N-(2-hydroxy-eicosanoyl)-1-beta-glucosyl-4E,6E-pentadecasphingadienine | [C41H77NO9 + 109Ag]+ | 836.47 | 836.46 | 12.0 |
|
| PG(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | [C46H71O10P + Na]+ | 837.47 | 837.47 | 0.0 |
|
| TG(16:1(9Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)) | [C55H92O6 + H]+ | 849.70 | 849.70 | 0.0 |
|
| [PC (3:0/3:0/3:0)] 1-(2E,6E,10E-phytatrienyl)-2-(2E,6E10E-phytatrienyl)-sn-glycero-3-phosphocholine | [C48H88NO6P + 107Ag]+ | 912.54 | 912.54 | 0.0 |
|
| PG(O-20:0/19:1(9Z)) | [C45H89O9P + 109Ag]+ | 913.53 | 913.53 | 0.0 |
|
| PG(22:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | [C50H85O10P + K]+ | 915.56 | 915.55 | 10.9 |
|
| PC(22:4(7Z,10Z,13Z,16Z)/P-18:1(11Z)) | [C48H86NO7P + 107Ag]+ | 926.51 | 926.52 | −10.8 |
|
| PS(17:0/22:1(11Z)) | [C45H86NO10P + 109Ag]+ | 940.51 | 940.50 | 10.6 |
|
| PIP(16:0/18:0) | [C43H84O16P2 + Na]+ | 941.51 | 941.51 | 0.0 |
|
| LacCer(d18:0/14:0) | [C44H85NO13 + 107Ag]+ | 942.51 | 942.51 | 0.0 |
|
| PI(17:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z)) | [C44H73O13P + 107Ag]+ | 947.39 | 947.38 | 10.6 |
| [C44H73O13P + 109Ag]+ | 949.39 | 949.38 | 10.5 | ||
|
| PS(P-20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | [C48H82NO9P + 107Ag]+ | 954.49 | 954.48 | 10.5 |
| [C48H82NO9P + 109Ag]+ | 956.48 | 956.48 | 0.0 | ||
|
| PI(O-16:0/20:2(11Z,14Z)) | [C45H85O12P + 107Ag]+ | 955.49 | 955.48 | 10.5 |
|
| PI(15:0/20:1(11Z)) | [C44H83O13P + 107Ag]+ | 957.47 | 957.46 | 10.4 |
|
| PI(17:1(9Z)/20:3(8Z,11Z,14Z)) | [C46H81O13P + 109Ag]+ | 981.44 | 981.45 | −10.2 |
|
| TG(19:1(9Z)/21:0/21:0) | [C64H122O6 + H]+ | 987.94 | 987.93 | 10.1 |
|
| 5-formyl-tetrahydrosarcinapterin | [C36H52N7O20P + 107Ag]+ | 1040.21 | 1040.21 | 0.0 |
|
| Lipid IVA | [C68H126N2O23P2 + H]+ | 1401.84 | 1401.83 | 7.1 |
|
| Tetrahexosylceramide (d18:1/26:1(17Z)) | [C70H128N2O23 + K]+ | 1403.85 | 1403.85 | 0.0 |
* Putative metabolite.
Figure 5Exemplary chromatograms obtained during the analysis of selected compounds by HPLC. L—lactose; LA—lactic acid; B2—riboflavin; B3—niacin; B9—folic acid; tR—retention time.
Concentration of the analyzed vitamins in the niacin assay medium and the post-culture fluid of LAB strains obtained using HPLC analysis. During the analysis, the concentrations of the analyzed vitamins in the clean medium were taken into account (values for LAB strains shown in the table are after background subtraction). nd—not detected; LOD—limit of detection; LOQ—limit of quantification.
| Concentration (µg/mL) | |||
|---|---|---|---|
| Sample | Niacin—B3 | Folic Acid—B9 | Riboflavin—B2 |
| TEMPERATURE 20 °C | |||
| Niacin Assay Medium | 0.178 ± 0.009 | nd | 4.104 ± 0.126 |
|
| 3.582 ± 0.132 | nd | 1.409 ± 0.045 |
|
| nd | LOD | −2.276 ± 0.118 |
| MRS Broth Medium | nd | nd | nd |
|
| 0.718 ± 0.000 | nd | 0.147 ± 0.006 |
|
| 1.465 ± 0.188 | nd | 0.109 ± 0.002 |
| TEMPERATURE 30 °C | |||
| Niacin Assay Medium | 0.174 ± 0.001 | nd | 4.592 ± 0.095 |
|
| 1.273 ± 0.177 | LOD | 0.754 ± 0.065 |
|
| 0.081 ± 0.005 LOQ | LOD | −0.307 ± 0.495 |
| MRS Broth Medium | 1.350 ± 0.073 | nd | 4.011 ± 0.067 |
|
| −0.874 ± 0.072 | nd | −3.871 ± 0.001 |
|
| −0.872 ± 0.058 | nd | −1.314 ± 0.115 |
Concentration of the analyzed compounds in the LAPTg medium and the post-culture fluid of LAB strains obtained using HPLC analysis. During the analysis, the concentrations of the analyzed lactose and lactic acid in the clean medium were taken into account (values for LAB strains shown in the table are after background subtraction).
| Sample | Lactose (µg/mL) | Lactic Acid (µg/mL) |
|---|---|---|
| TEMPERATURE 20 °C | ||
| LAPTg Medium | 38.61 ± 0.58 | 34.01 ± 1.88 |
|
| 2.61 ± 0.81 | 1014.99 ± 47.59 |
|
| 14.49 ± 1.14 | 310.99 ± 7.48 |
| TEMPERATURE 30 °C | ||
| LAPTg Medium | 49.91 ± 1.00 | 16.43 ± 0.22 |
|
| 12.38 ± 0.95 | 638.21 ± 8.03 |
|
| 0.91 ± 0.50 | 277.36 ± 5.82 |
Results of the experiment aimed at examining the antagonistic properties of LAB strains against pathogenic bacteria.
| Pathogenic Strain | Number of Grown Pathogen Colonies (Percentage of Inhibition) | ||
|---|---|---|---|
| Control |
|
| |
|
| 340 ± 63 | 174 | 156 |
| 49% | 54% | ||
|
| 62 ± 13 | 22 | 5 |
| 65% | 92% | ||
|
| 204 ± 12 | 0 | 0 |
| 100% | 100% | ||
|
| 956 ± 35 | 0 | 0 |
| 100% | 100% | ||